Focusing on the role of secretin/adhesion (Class B) G protein-coupled receptors in placental development and preeclampsia

Aiqi Yin¹, Xiaonian Guan¹, Jian V. Zhang²,³,⁴* and Jianmin Niu¹*

¹Department of Obstetrics, Shenzhen Maternity and Child Healthcare Hospital, The First School of Clinical Medicine, Southern Medical University, Shenzhen, China, ²Center for Energy Metabolism and Reproduction, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China, ³Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China, ⁴Shenzhen Key Laboratory of Metabolic Health, Shenzhen, China

Preeclampsia, a clinical syndrome mainly characterized by hypertension and proteinuria, with a worldwide incidence of 3–8% and high maternal mortality, is a risk factor highly associated with maternal and offspring cardiovascular disease. However, the etiology and pathogenesis of preeclampsia are complicated and have not been fully elucidated. Obesity, immunological diseases and endocrine metabolic diseases are high-risk factors for the development of preeclampsia. Effective methods to treat preeclampsia are lacking, and termination of pregnancy remains the only curative treatment for preeclampsia. The pathogenesis of preeclampsia include poor placentation, uteroplacental malperfusion, oxidative stress, endoplasmic reticulum stress, dysregulated immune tolerance, vascular inflammation and endothelial cell dysfunction. The notion that placenta is the core factor in the pathogenesis of preeclampsia is still prevailing. G protein-coupled receptors, the largest family of membrane proteins in eukaryotes and the largest drug target family to date, exhibit diversity in structure and function. Among them, the secretin/adhesion (Class B) G protein-coupled receptors are essential drug targets for human diseases, such as endocrine diseases and cardiometabolic diseases. Given the great value of the secretin/adhesion (Class B) G protein-coupled receptors in the regulation of cardiovascular system function and the drug target exploration, we summarize the role of these receptors in placental development and preeclampsia, and outlined the relevant pathological mechanisms, thereby providing potential drug targets for preeclampsia treatment.

KEYWORDS
preeclampsia (PE), pathogenesis, placenta, secretin GPCRs, adhesion GPCRs
Introduction

Preeclampsia (PE) is a multisystem pregnancy disorder characterized by new-onset hypertension after 20 weeks of gestation and affects the functions of multiple organs (Brown et al., 2018; Chappell et al., 2021). PE influences around 3–8% of the pregnant women and remains a key cause of maternal mortality, bringing about at least 42,000 maternal deaths each year (Abalos et al., 2013; Say et al., 2014). PE seriously threatens maternal and fetal life safety, leading to many severe complications such as acute renal failure, intracranial hemorrhage, fetal growth restriction (FGR), abnormal fetal heart development and still birth (Adu-Bonsaffoh et al., 2013; Brown et al., 2018; Hutcheon et al., 2011). Furthermore, PE can bring substantial long-term cardiovascular and endocrine metabolic risks both to the mother and the child (Bellamy et al., 2007; Kajantie et al., 2009; Mongraw-Chaffin et al., 2010; Tuovinen et al., 2012). The strong evidence has demonstrated that aspirin can prevent the development of PE (Duley et al., 2019; Jin, 2021). However, once PE occurs, the existing treatments, such as antispasmodic and antihypertensive agents, cannot prevent the progression of the disease. The termination of pregnancy is the only effective treatment for PE, which may leads to the delivery of premature fetus or low birth weight fetus, with high healthcare costs (Chappell et al., 2021; Liu et al., 2009). Thus, it is necessary to explore new treatments for PE to reduce the risk and safely prolong pregnancy.

The pathophysiological mechanisms of PE have been studied for a long time. The placenta is the key factor responsible for the development of PE. All maternal complications share a common pathophysiological feature focusing on placental abnormalities (Burton et al., 2019). The pathogenesis of PE contains poor placentation, uteroplacental malperfusion and endothelial cell dysfunction (Brennan et al., 2014; Redman and Staff, 2015). However, due to the heterogeneity of PE and the diversity of its clinical manifestations, the immunological, genetic and environmental mechanisms of PE are still not fully understood, and there is no great breakthrough regarding

![Diagram of the secretin/adhesion GPCRs and the pathophysiology of preeclampsia.](https://BioRender.com)
### TABLE 1: The secretin/adhesion (class B) GPCRs in placental development and PE.

| Secretin (Class B) GPCRs | Species | GPCRs in placental development and PE | References |
|--------------------------|---------|--------------------------------------|------------|
| CRLR/CALCRL/CALCR        | Human   | Lowly expressed at the uterus and umbilical artery in pregnancy-induced hypertension | Makino et al. (2001) |
|                          | Human   | Expressed at the vascular endothelial cells of placental chorionic villi in the first trimester | Tsatsaris et al. (2002) |
|                          | Mouse   | Expressed in placenta and involved in blood flow | Dong et al. (2003) |
|                          | Human   | Regulates human fetoplacental vascular tone | Dong et al. (2004) |
|                          | Human   | Expressed in human trophoblast cell line JAR and HTR-8/SVneo | Zhang et al. (2005) |
|                          | Human   | Decreasingly expressed in preeclamptic placenta | Dong et al. (2005) |
|                          | Mouse   | Affects vasodilation in PE | Dackor et al. (2006) |
|                          | Mouse   | Leads to hydrops fetalis, cardiovascular defects and embryonic lethality in CALCRL KO mouse | onKeyDown |
|                          | Human   | Expressed in extravillous cytotrophoblast and decidua | Sirico et al. (2021) |
|                          | Human   | Influenes vascular resistance | onKeyDown |
|                          | Human   | Located in cultured human choriocarcinoma cells | Gao et al. (2007) |
|                          | Human   | Mediates expression of PGDH | Gao et al. (2008) |
|                          | Human   | Expressed in placental trophoblasts | Gao et al. (2012) |
|                          | Human   | Regulates prostaglandin production | onKeyDown |
|                          | Human   | Regulates estradiol and progesterone production in cultured human trophoblasts | Gao et al. (2012) |
|                          | Human   | Regulates glucose transporters in cultured human placental trophoblasts | Gao et al. (2012) |
|                          | Human   | Increasingly expressed via exogenous CRH stimulation in ReWo cells | Chen et al. (2013) |
| GCGR                     | Mouse   | Causes hypoglycemia, hyperglucagonemia and fetoplacental defects in GCGR KO mouse | Ouhilal et al. (2012) |
| GLP1R                    | Mouse   | Attenuates placental ischemia | Younes et al. (2020) |
| PAC1/ADCYAP1R1           | Human/mouse | Expressed in human and rat placenta | Scaldaferri et al. (2000) |
|                          | Mouse   | As binding sites for PACAP in human tissue | Koh et al. (2003) |
|                          | Human   | Expressed in decidual cells, chorionic vessels and stromal cells | |>842x0.5
|                          | Human   | Dynamically expressed during gestation | onKeyDown |
|                          | Human   | Regulates MAPK signaling pathways in cytotrophoblasts | Reglo et al. (2008) |
| ADGRA2 (GPR124)          | Mouse   | Causes embryonic lethality, CNS-specific angiogenesis arrest and hemorrhage in GPR124 KO mouse | Kuhner et al. (2010) |
|                          | Mouse   | Results in embryonic lethality in GPR124 global KO mouse and GPR124 conditional (endothelial-specific) KO mouse | Cullen et al. (2011) |
|                          | Human   | Lowly expressed in early-onset PE with comparison of late-onset PE | Liang et al. (2016) |
|                          | Mouse   | Leads to embryonic lethality in GPR124 KO mouse | Chang et al. (2017) |
|                          | Mouse   | Causes vascular remodeling defects and postnatal kidney failure | Lu et al. (2017) |
|                          | Mouse   | Possesses strict expression pattern | Moriguchi et al. (2004) |
|                          | Mouse   | Required for embryonic development | Waller-Evans et al. (2010) |
|                          | Human   | Related to placental angiogenesis in IUGR | Majewska et al. (2019) |

(Continued on following page)
the treatment for PE. Some research scholars advocate that PE should be reclassified using placenta-derived markers or new phenotypic combinations, which may assist in identifying high-risk patients, monitoring disease progression, and providing effective clinical interventions (Ferrazzi et al., 2018; Powers et al., 2021).

G protein-coupled receptors (GPCRs), the largest family of membrane proteins in eukaryotes, are involved in the regulation of almost all life processes and functions. GPCRs are the key factors for the occurrence and development of major diseases, including cardiometabolic diseases (Dorsam and Gutkind, 2007; Lappano and Maggiolini, 2011; Wang et al., 2018). Exploratory studies have revealed the essential functions of GPCRs in placental development and provided a sufficient theoretical basis that they can be used as potential targets for PE (Conrad, 2016; McGuane and Conrad, 2012; Quitterer and AbdAlla, 2021). Based on the classification by structure and phylogeny analysis of GPCRs, Class B GPCRs, which are structurally characterized by large extracellular regions, contain the following two families, secretin GPCRs and adhesion GPCRs. Secretin GPCRs are polypeptide hormone receptors that can mediate diverse physiological activities. Adhesion GPCRs are indispensable for human development, and their mutations are involved in all major tissues diseases. This review summarizes the pathophysiological mechanisms of PE and the biological role of secretin/adhesion (Class B) GPCRs in placental development and PE, aiming to find potential markers for the reclassification and treatment of PE.

Pathophysiology of PE: the two-stage placental model

The clinical symptoms of PE are immediately relieved once the placenta is delivered, suggesting that the placenta is crucial for the pathogenesis of PE. The two-stage placental model theory proposed by professor Redman is the most acceptable explanation for the pathogenesis of PE (Redman, 1991). In the first stage (preclinical and placental period), insufficient trophoblast infiltration causes the incomplete remodeling of the uterine spiral arteries, resulting in poor placentation and placental dysfunction. In the second stage (clinical and maternal disease period), placental ischemia, hypoxia and oxidative stress lead to the release of numerous inflammatory factors into the circulation, including soluble fms-like tyrosine kinase-1 (sFlt-1), soluble endoglin (sEng), trophoblast debris and reactive oxygen species (Levine et al., 2004; Maynard et al., 2003). These factors cause systemic vascular inflammation and extensive maternal endothelial cell dysfunction (Redman et al., 1999) and provoke diverse clinical manifestations such as maternal hypertension, proteinuria and FGR (Powe et al., 2011). This two-stage model is established on the assumption that poor placentation, predominantly leading to FGR, occurs in almost all PE cases (Avagliano et al., 2011). However, some of the late-onset PE patients with full delivery show unlimited neonatal growth, which suggests that poor placentation does not happens in all PE placenta (Xiong et al., 2002). The second placental cause of PE is uteroplacental malperfusion. The placenta capacity over the capacity of the uterus could compress the terminal villi and hinder intervillous perfusion, resulting in syncytiotrophoblast hypoxia and the subsequent placental dysfunction (Devisse et al., 2013). Increased syncytiotrophoblast apoptosis in the human full-term placenta may cause PE as well (Ishihara et al., 2002). Studies have shown that the angiogenesis-related factors secreted by syncytiotrophoblasts are expected to be circulating biomarkers for the diagnosis and prediction of PE (Droge et al., 2021). Excessive trophoblastic senescence increases placental cell stress, which may be a potential pathogenic factor for PE (Zaki et al., 2003; Zhang et al., 2021). Overall, syncytiotrophoblast stress is a common end point of both early-onset and late-onset PE pathways and is affected by maternal genetic, epigenetic and environmental factors. Syncytiotrophoblast stress signaling in the maternal
circulation may be the most specific biomarker of PE (Redman et al., 2022). The two-stage model summarizes the pathophysiological mechanisms of PE into two stages (placental dysfunction and clinical manifestations) and three ways (poor placentation, dysfunctional uteroplacental perfusion and placental aging) (Figure 1). In addition, it incorporates a range of pathophysiological mechanisms, including dysregulated immune tolerance, vascular inflammation, endoplasmic reticulum stress and oxidative stress (Sheppard and Bonnar, 1976). Maternal and pregnancy risk factors, such as primiparity, obesity and chronic prepregnancy disorders, are also considered (Alnaes-Katjavivi et al., 2016; Egeland et al., 2016; Skjaerven et al., 2002; Tannetta et al., 2015).

Role of GPCRs in PE

GPCRs, a superfamily of seven-transmembrane receptors, more than 800 of which are encoded in the human genome, constitute the largest family of cell surface receptors in mammalian cells. GPCRs were initially divided into A–F systems according to the structural similarity of their receptor size, ligand interaction points and phylogeny. Their prototype members are as follows: Class A (rhodopsin receptors), Class B (secretin/adhesion receptors), Class C (metabotropic glutamate receptors), Class D (fungal mating pheromone receptors), Class E (cyclic AMP receptors) and Class F (frizzled/smoothened receptors) (Attwood and Findlay, 1994; Bockaert and Pin, 1999). Fredriksson et al. provided a GRAFS classification approach based on an overall phylogenetic analysis of human tracks that consists of the following five families: rhodopsin (Class A), secretin/adhesion (Class B), glutamate (Class C), frizzled (Class F) and taste 2 (Class T) (Fredriksson et al., 2003). GPCRs can recognize various different ligands or stimuli, such as hormones, neurotransmitters and light, to regulate key physiological processes. Abnormal GPCR signaling can lead to various diseases, such as diabetes (Riddy et al., 2018; Wu et al., 2021), cardiovascular diseases (Wang et al., 2018) and cancers (Dorsam and Gutkind, 2007; Lappano and Maggiolini, 2011). More than 40% of commercial drugs exert their efficacy through GPCRs. Most drugs target rhodopsin GPCRs because they have various ligands, but other GPCRs also possess distinct therapeutic potential, such as more than 34 drugs targeting secretin GPCRs and 21 drugs targeting glutamate GPCRs (Hutchings, 2020). Furthermore, research on drugs targeting GPCRs are still increasing (Zhou and Wild, 2019).

The GPCRs-targeted drugs such as GLP-1, which belongs to secretin GPCRs, have been used for the treatment of cardiovascular diseases and endocrine diseases. The GPCR-mediated regulation of vascular tone and circulating blood volume plays crucial roles in the maintenance of blood pressure homeostasis. PE is inextricably linked to endocrine and cardiovascular diseases. Recently, it’s found GPCRs potentially contribute to maternal physiological adaptation to pregnancy and placentation development. Several GPCRs such as calcitonin receptor-like receptor (CRLR) and angiotensin AT1/2 are potential therapeutic targets for PE. They can modulate systemic and/or uteroplacental vasodilation to alleviate hypertension in PE (Dong et al., 2006). Secretin and adhesion GPCRs, which belong to the class B GPCR family, present great potential in clinical use. Many studies are committed to investigate the fundamental role of Class B (secretin/adhesion) GPCRs in PE, so it is necessary to summarize the current research progress. A comprehensive summary of the researches in relation to Class B (secretin/adhesion) GPCRs in the field of placental development and PE is provided in the following part of this review (Table 1).

Secretin (Class B) GPCRs

The secretin family, a small part of GPCRs containing 15 members, has large extracellular domains that can bind to hormone and mainly regulates metabolism (Lagerstrom and Schioth, 2008).

Calcitonin receptor-like receptor (CRLR) is required for embryonic development (Chang and Hsu, 2013). Deficiency of CRLR causes extreme hydrops fetalis and embryonic death (Dackor et al., 2006; Mackie et al., 2018). CRLR is widely expressed in vascular endothelial cells of placental chorionic villi at the first trimester, human choriocarcinoma JAr cells and trophoblast HTR-8/svneo cells (Tsatsaris et al., 2002). It shows a spatiotemporal pattern in the female reproductive system of pregnant rats (Li et al., 2010). An analysis of mouse placenta obtained on E18 of pregnancy suggests that CRLR is predominantly expressed in trophoblast, syncytiotrophoblast and trophoblast giant cells (Chang and Hsu, 2013; Dong et al., 2003; Zhang et al., 2005). CRLR regulates trophoblast proliferation and differentiation in the implantation process (Tsatsaris et al., 2002). Existing research demonstrates that CRLR is decreasingly expressed at the uterus and umbilical artery tissues in pregnancy-induced hypertension patients (Makino et al., 2001) and at PE placenta (Dong et al., 2005). It also associates with PE in vascular remodeling (Chang and Hsu, 2013). The impairment of CRLR associated with calcitonin gene-related peptide (CGRP)-dependent vasodilation in PE (Dong et al., 2005) suggest their role in the control of human fetoplacental vascular tone. CGPR-mediated vascular dilation involves the activation of KATP channels, cAMP and nitric oxide pathway (Dong et al., 2004). The loss of CRLR associated receptor activity-modifying proteins (RAMPs) reduces the expression of parathyroid hormone 1 receptor (PTHR1) (Kadmiel et al., 2017). PTHR1 expresses differently depending on maternal hyperglycemia type. It’s highly expressed in the extravillous cytotrophoblasts and decidua tissues, regulating the human
trophoblast-derived JEG-3 cell proliferation (Hellman et al., 1993), and committing to adverse pregnancy outcomes (Sirico et al., 2021).

Corticotropin releasing hormone (CRH) promotes embryo implantation (Makrigiannakis et al., 2001). It also control trophoblast invasion by downregulating the synthesis of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in extravillous trophoblast (EVT) cells (Bamberger et al., 2006). Abnormalities in trophoblast invasion may lead to abnormal placentation. The treatment of BeWo cells with exogenous CRH results in the elevation of cellular corticotropin releasing hormone receptor 1 (CRHR1) levels, which are significantly reduced in PE and intrauterine growth restriction (IUGR) (Chen et al., 2013; Karteris et al., 2003). CRHR1 and CRHR2 are expressed in placental trophoblasts, and they regulate estradiol and progesterone production as well as glucose transporters through distinct signaling pathways. They exert differential effects on 15 hydroxy prostaglandin dehydrogenase (PGDH) expression (Gao et al., 2007; Gao et al., 2008; Gao et al., 2012a; Gao et al., 2012b; Karteris et al., 1998). The deficiency of CRHR1 in uterine at early pregnancy implicates the pathogenesis of recurrent miscarriage, placenta accreta and PE (Kalantaridou et al., 2007).

The absence of the glucagon receptor (GCGR) gene during pregnancy leads to abnormal placentation and poor fetal growth, increasing occurrence rate of fetal and early postnatal death. The placenta affected by GCGR are characterized by extensive mineralization, fibrinoid necrosis, narrowing of the vascular channels and thickened interstitium associated with trophoblast hyperplasia. In addition, the lack of GCGR downregulates genes that control growth, vascularization and oxidative stress (Charron and Vuguin, 2015; Ouhilal et al., 2012). Regarding glucagon-like peptide receptors (GLPRs, including GLP1R and GLP2R), it’s found that the GLP1R agonist liraglutide can increase nitric oxide production and decrease blood pressures. They function partially through activating nitric oxide synthase (NOS) and thus serve as a potential therapeutic option for PE (Younes et al., 2020).

Pituitary adenylate cyclase activating polypeptide receptor 1 (PAC1), expressed in both human and mouse placenta, has spatiotemporal expression characteristics in decidual cells, chorionic vessels and stromal cells (Koh et al., 2003; Koh et al., 2005; Scaldaferrri et al., 2000). Its antagonist PACAP6-38 can activate MAPK signaling in human cytotrophoblasts, which suggests the possible role in gestational maintenance and fetal growth (Reglodi et al., 2008). Drugs designed on the basis of secretin GPCRs have been developed and applied for clinical use, especially in the treatment of metabolic diseases, such as diabetes. Given diabetes and obesity are risk factors for PE, the prospect of secretin GPCRs in therapy of PE could be speculated.

Adhesion (Class B) GPCRs

The adhesion family of GPCRs, a large branch with 33 members, is the second largest family of GPCRs separated from secretin GPCRs. The International Union of Basic and Clinical Pharmacology (IUPHAR) rename adhesion GPCRs as ADGRs followed a letter and a number to denote their subfamily and subtype, respectively (Hamann et al., 2015). Adhesion GPCRs are paid close attention due to its specific biological function and structure. Most adhesion GPCRs have long diverse N termini, and their N termini are rich in functional domains that can be found in other proteins, such as cadherins, lectins and immunoglobulins. It’s shown that the number and structure of these domains are essential for the specificity of receptor ligand binding interactions (Bjarnadottir et al., 2004; Purcell and Hall, 2018).

Several adhesion GPCRs participate in angiogenesis, a process that implicates in gestational physiology, placental development and the occurrence of PE (Masiero et al., 2013; Stellik et al., 2004; Vallon and Essler, 2006; Wang et al., 2005). ADGRA2 (GPR124) deficiency leads to embryonic lethality due to the central nervous system (CNS)- specific angiogenesis and hemorrhage (Anderson et al., 2011; Chang et al., 2017; Cullen et al., 2011; Kuhnert et al., 2010). The loss of ADGRF5 (GPR116) and ADGRL4 (ELTD1, ET1) result in vascular remodeling defects (Lu et al., 2017). Both ADGRA2 (GPR124) and ADGRG6 (GPR126) are required for embryonic development (Chang et al., 2017; Waller-Evans et al., 2010). ADGRG6 (GPR126) has a strictly regulated expression pattern in mouse development (Moriguchi et al., 2004). A differential expression of ADGRG6 (GPR126) is found in IUGR placenta, which is correlated with placental angiogenesis (Majewska et al., 2019) and hypoxia in early pregnancy (Bogias et al., 2022). ADGRG6 (GPR126) mutant placenta shows a decreased expression of proteases associated with trophoblast invasion and maternal uterine vascular remodeling, leading to IUGR, PE and early miscarriage. Hence, ADGRG6 (GPR126) is essential in the trophoblast lineage for the promotion of spiral artery remodeling during placental development (Torregrosa-Carrion et al., 2021). Our research group previously analyzes the gene expression profiles at placentas in early-onset PE and late-onset PE. ADGRA2 (GPR124) is downregulated in early-onset PE and involve in cell surface receptor-related signaling (Liang et al., 2016). The specific role and mechanism of ADGRA2 (GPR124) in placental development and PE are still under investigation. ADGRE5 (CD97) is downregulated in PE placenta and promotes trophoblast invasion by targeting FOXC2 through PI3K/Akt/mTOR signaling pathway (Shen et al., 2020). ADGRG2 (GPR64, HE6) plays a crucial role in the decidualization of endometrial stromal cells (Yoo et al., 2017). Adhesion GPCRs are considered as suitable targets.
for therapy, but the ligands of most members have not been found. And there are no associated drugs that are currently approved by the FDA.

Conclusion and perspectives

In summary, the Class B (secretin/adhesion) GPCRs play crucial roles in placental development and PE, suggesting that the class B (secretin/adhesion) GPCRs could serve as therapeutic targets in PE. However, most of the studies mainly focus on their expression level and associated phenotype, whereas the molecular mechanisms still need to be paid much more attention. Deep comprehension on the mechanisms is required to provide solid rationale for the application of Class B (secretin/adhesion) GPCR-targeted drugs into PE.

Author contributions

JZ and JN conceived the manuscript. AY, JZ and JN wrote and revised the manuscript. XG prepared the figure and the table. All authors contributed to the article and approved the submitted version.

References

Abalos, E., Caesta, C., Grossu, A. L., Chou, D., and Say, L. (2013). Global and regional estimates of preclampsia and eclampsia: A systematic review. Eur. J. Obstet. Gynecol. Reproductive Biol. 170 (1), 1–7. doi:10.1016/j.ejogrb.2013.05.005

Adu-Bonsahfi, K., Oppong, S. A., Binlnla, G., and Obed, S. A. (2013). Maternal deaths attributable to hypertensive disorders in a tertiary hospital in Ghana. Int. J. Gynecol. Obstetrics 123 (2), 110–113. doi:10.1016/j.ijog.2013.05.017

Almaes-Katypvri, P., Lyll, F., Roald, B., Redman, C. W., and Staff, A. C. (2016). Acute atherosis in vacuum suction biopsies of decidua basalis: An evidence based research definition. Placenta 37, 26–33. doi:10.1016/j.placenta.2015.10.020

Anderson, K. D., Pan, L., Yang, X. M., Hughes, V. C., Walls, J. R., Dominguez, M. G., et al. (2011). Angiogenic sprouting into neural tissue requires Gpr124, an orphan molecule-1 regulation. Proc. Natl. Acad. Sci. U.S.A. 108 (7), 2807–2812. doi:10.1073/pnas.1019761108

Atwood, T. K., and Findlay, J. B. (1994). Fingerprinting G-protein-coupled receptors. Protein Eng. Des. Sel. 7 (2), 195–203. doi:10.1093/protein/7.2.195

Avaglano, L., Bulfamante, G. P., Morabito, A., and Marconi, A. M. (2011). Abnormal spiral artery remodelling in the decidual segment during pregnancy: From histology to clinical correlation. J. Clin. Pathol. 64 (12), 1064–1068. doi:10.1111/j.1365-2141.2011.00092

Bamberger, A. M., Minas, V., Kalantarioud, S. N., Radde, J., Sadeghian, H., Linting, T., et al. (2006). Corticotropin-releasing hormone modulates human trophoblast invasion through carcinoembryonic antigen-related cell adhesion molecule-1 regulation. Am. J. Pathology 168 (1), 141–150. doi:10.2353/apjap.2006.050017

Bellamy, L., Casas, J. P., Hingorani, A. D., and Williams, D. J. (2007). Pre-eclampsia and risk of cardiovascular disease and cancer in later life: Systematic review and meta-analysis. BMJ 335 (7627), 974. doi:10.1136/bmj.39335.385301.BE

Bjarnadóttir, T. K., Fredriksson, R., Höglund, P. J., Gloriam, D. E., Lagerström, M. C., and Schöth, H. B. (2004). The human and mouse repertoire of the adhesion family of G-protein-coupled receptors. Genomics 84 (1), 23–33. doi:10.1016/j.ygeno.2003.12.004

Brown, M. A., Magee, L. A., Kenny, L. C., Karumanchi, S. A., McCarthy, F. P., Saito, S., et al. (2018). Hypertensive disorders of pregnancy. Hypertension 72 (1), 24–33. doi:10.1161/HYPERTENSIONAHA.117.10803

Burton, G. J., Redman, C. W., Roberts, J. M., and Moffett, A. (2019). Pre-eclampsia. Pathophysiology and clinical implications. BMJ 366,l2381. doi:10.1136/bmj.l2381

Chang, C. L., and Hsu, S. Y. (2013). Roles of CLR/RAMP receptor signaling in reproduction and development. Cpps 14 (5), 393–406. doi:10.2174/188920371349990056

Chang, J., Mancuso, R. M., Maier, C., Liang, X., Yuki, K., Yang, L., et al. (2017). Gp124 is essential for blood-brain barrier integrity in central nervous system disease. Nat. Med. 23 (4), 450–460. doi:10.1038/nm.4309

Chappell, L. C., Cliver, C. A., Kingdom, J., and Tong, S. (2021). Pre-eclampsia. Lancet 398 (10297), 341–354. doi:10.1016/S0140-6736(20)32335-7

Charron, M. J., and Voguin, P. M. (2015). Loss of glucagon receptor signaling and its implications beyond glucose homeostasis. J. Endocrinol. 224 (3), R123–R130. doi:10.1530/JOE-14-0614

Chen, Y., Allars, M., Pan, X., Maier, K., Angeli, G., Smith, R., et al. (2013). Effects of corticotropin releasing hormone (CRH) on cell viability and differentiation in the human hFeWo choriocarcinoma cell line. A potential synctialisation inducer distinct from cyclic adenosine monophosphate (cAMP). Reprod. Biol. Endocrinol. 11, 30. doi:10.1186/1477-7827-11-30

Funding

This work was supported by the National Natural Science Foundation of China (81830041 and 82001521), Guangdong Basic and Applied Basic Research Foundation (2019A1515110540), Shenzhen Science and Technology Program (JCYJ2019081217000666) and Shenzhen Key Laboratory of Metabolic Health (Grant No. ZDSYS2021042715240001).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Conrad, K. P. (2016). G-Protein-coupled receptors as potential drug candidates in pre-eclampsia: Targeting the relaxin-insulin-like family peptide receptor 1 for treatment and prevention. *Hum. Reprod. Update* 22 (6), 647–664. doi:10.1093/humupd/dmw021

Cullen, M., Elzarrad, M. K., Seaman, S., Zadina, E., Stevens, L., Yang, M. Y., et al. (2013). GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vasculature and establishment of the blood-brain barrier. *Proc. Natl. Acad. Sci. U.S.A.* 108 (14), 5759–5764. doi:10.1073/pnas.1207192108

Dackor, T. R., Fite-Six, K., Dunworth, W. P., Gibbons, C. L., Smithies, O., and Caron, K. M. (2006). Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene. *Mol. Cell. Biol.* 26 (7), 2511–2518. doi:10.1128/MCB.26.7.2511-2518.2006

Devisme, L., Merlot, B., Ego, A., Hourfain-Debarge, V., Deruelle, P., and Subtil, D. (2013). A case-control study of placental lesions associated with pre-eclampsia. *Int. J. Gynecol. Obstetrics* 120 (2), 165–168. doi:10.1016/j.ijsoc.2012.08.023

Dong, Y. L., Vegiraju, S., Chauhan, M., and Yallampalli, C. (2003). Expression of calcitonin-gene related peptide receptor components, calcitonin receptor-like receptor and receptor activity modifying protein 1, in the rat placenta during pregnancy and their cellular localization. *Mol. Hum. Reprod.* 9 (8), 481–496. doi:10.1093/mehrb/gag058

Dong, Y. L., Vegiraju, S., Chauhan, M., Gangula, P. R., Hankins, G. D., Goodrum, P. K. (2016). G-protein-coupled receptors as potential drug candidates in pregnancy. *Cochrane Database Syst. Rev.* 67 (6), 1173. doi:10.1002/14651858.CD004659.pub3

Doraiswamy, R. T., and Gutkind, J. S. (2007). G-protein-coupled receptors and cancer. *Nat. Rev. Cancer* 7 (2), 79–94. doi:10.1038/nrc2069

Dröge, L. A., Perschol, F. H., Stütz, N., Gafron, A., Frank, L., Busjahn, A., et al. (2021). Prediction of preeclampsia-related adverse outcomes with the sfb1 (soluble fms-like tyrosine kinase 1) sPCTF (placental growth factor)-ratio in the clinical routine. *Hypertension* 77 (2), 461–471. doi:10.1161/HYPERTENSIONAHA.120.15146

Duley, L., Mihet, S., Hunter, K. E., Saad, A. L., and Askle, M. I. (2019). Placenta: Antepartum platelets for preventing preeclampsia and its complications. *Cochrane Database Syst. Rev.* 2019 (10). CD004659:CD004659.pub3

Edgland, G. M., Klungsøy, K., Yen, N., Tell, G. S., Naess, O., and Skjerven, R. (2016). Preconception cardiovascular risk factor differences between gestational hypertenison and preeclampsia. *Hypertension* 67 (6), 1173–1180. doi:10.1161/HYPERTENSIONAHA.116.09709

Ferrazzi, E., Stampalija, T., Monasta, L., Di Martino, D., Vonck, S., and Gyselaers, W. (2018). Regulation of proliferation in JEG-3 cells by a 500-kDa Ca2+ sensor and prevention. *Hypertension* 67 (6), 1235–1242. doi:10.1161/HYPERTENSIONAHA.118.12370. doi:10.1210/jc.2002-07778

Fredriksson, R., Lagerström, M. C., Lundin, L. G., and Schiöth, H. B. (2003). The G-protein-coupled receptor family: An update. *Nat. Rev. Drug Discov.* 2 (11), 935–947. doi:10.1038/nrd1328

Gao, L., He, P., Shi, J., Liu, C., Dai, L., Hui, N., et al. (2007). Corticotropin-releasing hormone receptor type 1 and type 2 mediate differential effects on 15–2866 estradiol and progesterone production by CRH-R1 and -R2 is through divergent glucose transporters mediated by CRH receptor type 1 and type 2 in human placental trophoblasts. *Front. Endocrinol.* 477. doi:10.1152/ajpheart.00140.2003

Gao, L., Lu, C., Xu, C., Tao, Y., Cong, B., and Ni, X. (2008). Differential regulation of placental production mediated by corticotropin-releasing hormone receptor type 1 and type 2 in human placental trophoblasts. *Endocrinology* 149 (6), 2866–2876. doi:10.1210/en.2007-1377

Gao, L., Lv, C., Xu, C., Li, Y., Cai, X., Gu, H., et al. (2012a). Differential regulation of glucose transporters mediated by CRH-R1 type 1 and type 2 in human placental trophoblasts. *Endocrinology* 153 (3), 1464–1471. doi:10.1210/en.2011-1673

Gao, L., Tao, Y., Hu, T., Liu, W., Xu, C., Liu, J., et al. (2012b). Regulation of estradiol and progesterone production by CRH-R1 and -R2 is through divergent signaling pathways in cultured human placental trophoblasts. *Endocrinology* 153 (10), 4918–4927. doi:10.1210/endo.2012-1453

Hellman, P., Hellman, B., Juhlin, C., Jupner, H., Rastad, J., Rudefelt, P., et al. (1993). Regulation of proliferation in JEG-3 cells by a 500-kDa Ca2+ sensor and parathyroid hormone-related protein. *Archives Biochem. Biophys* 307 (2), 379–385. doi:10.1006/abbi.1993.1663

Hamann, J., Auvi, G., Arac, D., Engel, F. B., Formstone, C., Fredriksson, R., et al. (2013). International union of basic and clinical Pharmacology. *XCV.*
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to two conserved proteolytic cleavage sites.

Yin et al. 10.3389/fcell.2022.959239

Frontiers in Cell and Developmental Biology

DOI: 10.3389/fcell.2022.959239

PI3K/Akt/mTOR signaling pathway. 

Reprod. Sci. 27 (8), 1553–1561. doi: 10.1007/s11192-020-01183-w

Sheppard, B. L., and Bonnar, J. (1976). The ultrastructure of the arterial supply of the human placenta in pregnancy complicated by fetal growth retardation. BJOG: An Int. J. Obstet. 83 (12), 948–959. doi:10.1111/j.1471-0528.1976.tb00791.x

Sárcio, A., Dell’Aquila, M., Tartaglione, L., Moresi, S., Fari, G., Pitozzo, D., et al. (2021). PTH-RP and PTH-R1 expression in placentas from pregnancies complicated by gestational diabetes: New insights into the pathophysiology of hyperglycemia in pregnancy. Diagnostics 11 (8), 1356. doi: 10.3390/diagnostics11081356

Skjarven, R., Wilcox, A. J., and Lie, R. T. (2002). The interval between pregnancies and the risk of preeclampsia. N. Engl. J. Med. 346 (1), 33–38. doi:10.1056/NEJMoa011379

Stehlik, C., Kroismayr, R., Dorfleuter, A., Binder, R. R., and Lipp, J. (2004). Vigre—a novel inductive approach to drug discovery for endometrial cell lines. FERTS Lett. 569 (1-3), 149–155. doi:10.1016/febslet.2004.05.038

Tannetta, D. S., Hunt, K., Jones, C. I., Davidson, N., Coxon, C. H., Ferguson, D., et al. (2015). Synctiotrophoblast extracellular Vesicles from pre-eclampsia placentas differentially affect platelet function. PLoS One 10 (11), e0142538. doi:10.1371/journal.pone.0142538

Torregrosa-Carrion, R., Piñeiro-Sabarís, R., Síguero-Márquez, G., Grego-Bessa, J., Luna-Zurita, L., Fernandes, V. S., et al. (2021). Adhesion G protein-coupled receptor GPR126/Adgrg is essential for placental development. Sci. Adv. 7 (44), eabj8447. doi:10.1126/sciadv.0014047

Tsatsaris, V., Tarrade, A., Merviel, P., Garel, J. M., Segond, N., Julienne, A., et al. (2002). Calcitonin gene-related peptide (CGRP) and CGRP receptor expression at the human implantation site. J. Clin. Endocrinol. Metabolism 87 (9), 4383–4390. doi:10.1210/jc.2002-021038

Tunuvin, S., Rádkötön, K., Pezon, A. K. H., Mahi, M., Heinonen, K., Walbeck, K., et al. (2012). Hypertensive disorders in pregnancy and risk of severe mental disorders in the offspring in adulthood: The Helsinki Birth Cohort Study. J. Psychiatr. Res. 46 (5), 303–310. doi:10.1016/j.jpsychires.2011.11.015

Vallon, M., and Esler, M. (2006). Proteolytically processed soluble tumor endothelial marker (TEM) 5 mediates endothelial cell survival during angiogenesis by linking integrin αvβ3 to glycosaminoglycans. J. Biol. Chem. 281 (45), 34179–34188. doi:10.1074/jbc.M605291200

Waller-Evans, H., Prömel, S., Langenhan, T., Dixon, J., Zahn, D., Collidge, W. H., et al. (2010). The orphan adhesion GPCR GPR126 is required for utero-placental development in the mouse. PLoS One 5 (11), e14047. doi:10.1371/journal.pone.0014047

Wang, T., Ward, Y., Tian, L., Lake, G., Bueding, L., Stelett-Stevenson, W. G., et al. (2005). CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood 105 (7), 2836–2844. doi:10.1182/blood-2004-07-2879

Wang, J., Gaizer, C., and Rockman, H. A. (2018). G-Protein-Coupled receptors in heart disease. Circ. Res. 123 (6), 716–735. doi:10.1161/CIRCRESAHA.118.311403

Wu, C. T., Hilgendorf, K. I., Bevacqua, R. J., Harg, Y., Demeter, J., Kim, S. K., et al. (2021). Discovery of ciliary G protein-coupled receptors regulating pancreatic islet insulin and glucagon secretion. Dev. Cell 55 (7), 1243–1255. doi:10.1016/j.devcel.2021.04.001

Xiong, X., Demiankow, N. N., Saunders, L. D., Wang, F. L., and Fraser, D. W. (2002) Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am. J. Epidemiol. 155 (3), 203–209. doi:10.1093/aje/155.3.203

Yoo, J. Y., Ahn, J. I., Kim, T. H., Yu, S., Ahn, J. Y., Lim, J. M., et al. (2017). G-protein coupled receptor 64 is required for decidualization of endometrial stromal cells. Sci. Rep. 7 (1), 5021. doi:10.1038/s41598-017-03156-8

Younes, S. T., Maeda, K. J., Sassier, J., and Ryan, M. J. (2020). The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension. Am. J. Physiolog. Heart Circul. Physiolog. 318 (1), H72–H77. doi:10.1152/ajpheart.00486.2019

Zaki, M., Greenwood, C., and Redman, C. W. (2003). The spontaneous reversible of pre-eclampsia associated with parvovirus-induced hydrops and the placental theory of pre-eclampsia: A case report. BJOG: Int. J. Obstet. 110 (12), 1125–1126. doi:10.1111/j.1471-0528.2003.00360.x

Zhang, X., Green, K. E., Yallampalli, C., and Dong, Y. L. (2005). Adrenomedullin enhances invasion by trophoblast cell lines. J. Biol. Reprod. 73 (4), 619–626. doi:10.1093/jbr/bpi040.10.40436

Zhang, B., Kim, M. Y., Elliott, G., Zhou, Y., Zhao, G., Li, D., et al. (2021). Human placental cytotrophoblast epithelial dynamics over gestation and alterations in placental disease. Dev. Cell 56 (9), 1238–1252. doi:10.1016/j.devcel.2021.04.001

Zhao, J., and Wild, C. (2019). GPCR drug discovery: Emerging targets, novel approaches and future trends. Curr. Top. Med. Chem. 19 (16), 1363–1364. doi:10.2174/1568026619666190828093500